Metraipolis › archive › dc_51364fbcebb9

The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer — Europe PMC PMID:40788860

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/40788860
DOI: 10.1371/journal.pone.0327588
License (as archived): solo-consultazione
Archived: 2026-11-10T18:02:13.918Z
SHA-256 of the archived text: bdd128ba9637d4121114d41b37645befcc1d4f8c49cbce7cb2995b7dc29b8146
Stable URL of this page: https://metraipolis.com/documento/dc_51364fbcebb9

How to cite

The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer — Europe PMC PMID:40788860 — Europe PMC (en), https://europepmc.org/article/MED/40788860 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_51364fbcebb9 (Metraipolis archive dc_51364fbcebb9, sha256 bdd128ba9637d4121114d41b37645befcc1d4f8c49cbce7cb2995b7dc29b8146)

BibTeX

@misc{dc51364fbcebb9,
  title = {The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer — Europe PMC PMID:40788860},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40788860},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_51364fbcebb9; sha256 bdd128ba9637d4121114d41b37645befcc1d4f8c49cbce7cb2995b7dc29b8146},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40788860. Agents can read the archived copy with the MCP tool read_document.